-
Two more pharmaceutical companies have reviewed it, and the market war for oral hypoglycemic drugs is intensifying
Time of Update: 2022-04-15
But at the same time, with the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years .
-
Chinese medicine presents a new development pattern, how to grasp the main line?
Time of Update: 2022-04-15
For example, Ping An Securities looks at opportunities in the TCM industry from five main lines, including innovative TCM drugs, branded OTC TCM, TCM formula granules, TCM injections, and TCM medical services .
-
In the new year, B-class pharmaceutical stocks fell for four consecutive days
Time of Update: 2022-04-15
Due to the high stickiness of the CDMO industry, according to the company's "Follow "Molecules win molecules" strategy, and it is expected that the company's market share in the later stages will gradually increase as these projects funnel into the late clinical and commercial stages .
-
The field of oncology has become a decisive "highland" for a large number of multinational pharmaceutical companies
Time of Update: 2022-04-15
From the perspective of the clinical pipelines of major pharmaceutical companies, tumors are also the focus of new drug research and development .
-
Pharmaceutical companies actively deploy the API business and build the integrated advantage of API preparations
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, under the refined division of labor in the global pharmaceutical industry, as the upstream of chemical preparations, the pharmaceutical intermediates and chemical API industries have achieved rapid development .
-
Under the continuous transformation and upgrading of the pharmaceutical industry, personnel changes will become more frequent
Time of Update: 2022-04-15
In addition to AstraZeneca, many multinational pharmaceutical companies have also undergone major personnel adjustments this year: for example, the head of the Novartis Oncology Hematology Division resigned; the position of the head of the Takeda Oncology Division was finally settled after 2 months of vacancy ; Fresenius Kabi China changed its chief financial officer; Abbott's global vice president resigned, etc.
-
my country has entered a critical period of pharmaceutical innovation-driven transformation, and basic research is the source
Time of Update: 2022-04-15
Facing the future, my country needs to continuously promote the innovation of the pharmaceutical industry, such as improving the research and development of original and high clinical value products and the strategy of going overseas.
-
Next week, a new pharmaceutical stock will be subscribed for, focusing on APIs and preparations!
Time of Update: 2022-04-15
7424 million yuan respectively, with a three-year compound annual growth rate of net profit attributable to the parent company of 10.
54%; the company's net profit attributable to the parent was 34 million yuan, a year-on-year growth rate of 2.
-
The "14th Five-Year" Chinese medicine development plan deploys ten key tasks, and the industry development will usher in qualitative changes
Time of Update: 2022-04-15
Analysts said that the introduction of the "14th Five-Year Plan" for traditional Chinese medicine will promote the development of the industry and usher in a qualitative change .
-
Innovative traditional Chinese medicine drugs may usher in an outbreak, and several major bottlenecks remain to be resolved
Time of Update: 2022-04-15
At present, the traditional Chinese medicine technical equipment industry still has difficulties such as low investment in research and development, lack of research talents, limited key technologies, and backward enterprise management .
-
The Chinese medicine sector strengthened, and Xinguang Pharmaceutical rose nearly 15%
Time of Update: 2022-04-15
As of February 24, a number of proprietary Chinese medicine companies have released their 2021 performance reports, including Pien Tze Huang, Shou Xian Gu, Ji Chuan Pharmaceutical, etc.
-
In 2030, the domestic in vitro diagnostic market will reach 288.2 billion yuan, and the space to replace the import of high-end production equipment is to be opened
Time of Update: 2022-04-15
It is understood that in the medical and health field, the main product of Kerui Technology is the automatic filling line equipment for in vitro diagnostic reagents (IVD), but it currently accounts for a small amount of the company's overall revenue .
-
How should local new drugs go overseas?
Time of Update: 2022-04-15
Judging from the achievements of local new drugs in the process of going overseas, there are currently 5 local innovative drugs that have been successfully approved abroad, including the prescription drug Kanglaite injection for the treatment of cancer, BeiGene's zanubrutinib, and Frontier Bio's Aibo Weitai, Chidamide from Microchip Bio, and Prokalutamide from Kintor Pharmaceuticals, etc.
-
API companies are accelerating the expansion of production capacity, which is having a positive impact on the pharmaceutical machine industry
Time of Update: 2022-04-15
It is planned to build a new production line project with an annual output of 308 tons of characteristic raw materials and 200 million tablets of anti-tumor preparations in the Cangshan industrial agglomeration area in Tiantai .
-
Cell gene therapy may take over biopharmaceuticals in the future, bringing new growth points to the pharmaceutical machinery industry
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, with the rapid development of biopharmaceutical technology, the continuous increase in R&D investment of pharmaceutical companies, and the support of a series of favorable policies, superimposed on the impact of the epidemic, China's biopharmaceutical industry has developed rapidly.
-
In the first half of the year, the market of Chinese medicinal materials was still at a high level, and the prices of a large number of varieties continued to rise.
Time of Update: 2022-04-15
According to relevant data, among the 1,445 varieties monitored by the market, there were 55 varieties of Chinese medicinal materials whose prices rose in March .
-
What are the pharmaceutical investment strategies in March?
Time of Update: 2022-04-15
The agency believes that the pharmaceutical sector has ushered in a good opportunity for layout recently, and it is recommended that investors focus on traditional Chinese medicine consumer goods/innovative drugs/low valuations, low expectations, and varieties with upward business trends/supply chain independent and controllable related targets .
-
Domestic medical device innovation is accelerating, but these aspects still need to be improved
Time of Update: 2022-04-15
Two innovative medical device products, the "Digestive Tract Vibrating Capsule System" produced by the company have been approved for the market .
-
The accelerated reshuffle of the pharmaceutical market is affecting a large number of enterprises!
Time of Update: 2022-04-15
At present, in order to expand production and develop higher quality, many pharmaceutical companies are building new manufacturing bases and upgrading and using more efficient and energy-saving pharmaceutical equipment.
-
Recently, pharmaceutical companies are starting the pace of intensive listing!
Time of Update: 2022-04-15
In addition, according to the "Initial Public Offering of Stocks on the Science and Technology Innovation Board Listing Announcement" previously issued by First Pharmaceutical Holdings, it will also be listed on the Shanghai Stock Exchange on March 23, 2022, at a price of 39.
